Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis
The management of rheumatoid arthritis (RA) has significantly improved, but a substantial number of patients still experience persistent disease activity, leading to the concept of 'difficult-to-treat RA' (D2T RA). The European Alliance of Associations for Rheumatology (EULAR) has provided a pivotal definition for D2T RA to unify clinical approaches and research methods. This definition frames D2T RA as an umbrella term for a diverse group of patients with management challenges stemming from various factors, including biological resistance, patient experience, and clinical complexities. This framework is invaluable for a previously ill-defined population, but its real-life application highlights areas for ongoing consideration and potential refinement. Here, we discuss some of the strengths and limitations of the EULAR definition for D2T RA.
Authors
- Maya H Buch (ORCID: https://orcid.org/0000-0002-8962-5642)
- György Nagy (ORCID: https://orcid.org/0000-0003-1198-3228)
Institutions
- Semmelweis University (HU)
- Manchester Academic Health Science Centre (GB)
- NIHR Oxford Musculoskeletal Biomedical Research Centre (GB)
- Manchester University NHS Foundation Trust (GB)
- NIHR Manchester Biomedical Research Centre (GB)
Publication Details
- Journal
- RMD Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-006271
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- National Institute for Health and Care Research
- Semmelweis Egyetem